Prieto V - Search Results

1

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.

Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA. Wyman K, et al. Among authors: prieto v. Cancer. 2006 May 1;106(9):2005-11. doi: 10.1002/cncr.21834. Cancer. 2006. PMID: 16565971 Free article. Clinical Trial.

2

Severe periorbital edema secondary to STI571 (Gleevec).

Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM, Talpaz M. Esmaeli B, et al. Cancer. 2002 Aug 15;95(4):881-7. doi: 10.1002/cncr.10729. Cancer. 2002. PMID: 12209733 Free article.

3

Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array.

Shen SS, Zhang PS, Eton O, Prieto VG. Shen SS, et al. J Cutan Pathol. 2003 Oct;30(9):539-47. doi: 10.1034/j.1600-0560.2003.00090.x. J Cutan Pathol. 2003. PMID: 14507401

4

Biochemotherapy in patients with metastatic anorectal mucosal melanoma.

Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY. Kim KB, et al. Cancer. 2004 Apr 1;100(7):1478-83. doi: 10.1002/cncr.20113. Cancer. 2004. PMID: 15042682 Free article.

5

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.

Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. Chen LL, et al. Cancer Res. 2004 Sep 1;64(17):5913-9. doi: 10.1158/0008-5472.CAN-04-0085. Cancer Res. 2004. PMID: 15342366

6

Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction.

Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M. Berger AJ, et al. Cancer Res. 2005 Dec 1;65(23):11185-92. doi: 10.1158/0008-5472.CAN-05-2300. Cancer Res. 2005. PMID: 16322269

7

Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.

Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Johnson FM, et al. Cancer. 2006 Jan 15;106(2):366-74. doi: 10.1002/cncr.21640. Cancer. 2006. PMID: 16342249 Free article. Clinical Trial.

8

Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma.

Pawlik TM, Ross MI, Prieto VG, Ballo MT, Johnson MM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Pawlik TM, et al. Cancer. 2006 Feb 15;106(4):900-6. doi: 10.1002/cncr.21635. Cancer. 2006. PMID: 16411225 Free article.

9

Nuclear expression of the antiapoptotic protein survivin in malignant melanoma.

Ding Y, Prieto VG, Zhang PS, Rosenthal S, Smith KJ, Skelton HG, Diwan AH. Ding Y, et al. Cancer. 2006 Mar 1;106(5):1123-9. doi: 10.1002/cncr.21727. Cancer. 2006. PMID: 16456815 Free article.

10

Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).

Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG. Ivan D, et al. J Cutan Pathol. 2006 Apr;33(4):280-5. doi: 10.1111/j.0303-6987.2006.00432.x. J Cutan Pathol. 2006. PMID: 16630177

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

622 results

Search Page

Filters